Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MCHR2 | Q969V1 | 4/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21026071 | 0.90 | SIGMAR1 (0.48) | MCHR1SIGMAR1ALDH1A1 | |
| SCHEMBL21026002 | 0.89 | MCHR1 (0.53) | MCHR1CYP3A4CYP2C19KDM4EMCHR2 | |
| SCHEMBL21026073 | 0.84 | SIGMAR1 (0.51) | CYP3A4KDM4ERECQLSIGMAR1ALDH1A1 | |
| SCHEMBL17678169 | 0.82 | KMO (0.58) | MCHR1MCHR2SIGMAR1 | |
| SCHEMBL14093244 | 0.80 | HDAC3 (0.46) | MCHR1CYP3A4CYP2C19MCHR2 | |
| SCHEMBL13483883 | 0.79 | SIGMAR1 (0.48) | MCHR1CYP3A4CYP2C19SIGMAR1 | |
| SCHEMBL6069755 | 0.79 | MCHR1 (0.47) | MCHR1MCHR2SIGMAR1 | |
| SCHEMBL17678223 | 0.79 | KMO (0.58) | MCHR1MCHR2 | |
| SCHEMBL4539220 | 0.79 | MCHR1 (0.47) | MCHR1CYP3A4CYP2C19MCHR2 | |
| SCHEMBL21026066 | 0.78 | HTR7 (0.51) | MCHR1MCHR2ALDH1A1SMN1; SMN2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | MCHR1 3488/4885CYP3A4 3390/4885CYP2C19 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.